{"nctId":"NCT02399345","briefTitle":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults","startDateStruct":{"date":"2015-03"},"conditions":["Chronic Hepatitis C Virus (HCV Infection Genotype 1)"],"count":10,"armGroups":[{"label":"Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir, dasabuvir","Drug: sofosbuvir (SOF)","Drug: ribavirin (RBV)"]}],"interventions":[{"name":"ombitasvir/paritaprevir/ritonavir, dasabuvir","otherNames":["Viekira PAK","ombitasvir also known as ABT-267","paritaprevir also known as ABT-450","dasabuvir also known as ABT-333"]},{"name":"sofosbuvir (SOF)","otherNames":[]},{"name":"ribavirin (RBV)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female at least 18 years of age at time of screening\n2. Chronic Hepatitis C virus (HCV) infection prior to study enrollment\n3. Screening laboratory results from the central clinical laboratory indicating HCV genotype 1 infection only\n4. Absence of cirrhosis and advanced bridging fibrosis\n\nExclusion Criteria:\n\n1. Positive test result for hepatitis B surface antigen (HbsAg) or human immunodeficiency virus (HIV) positive immunoassay\n2. Clinically significant abnormalities or co-morbidities, other than HCV infection, that make the subject an unsuitable candidate for this study or treatment with Ribavirin (RBV) in the opinion of the investigator\n3. Any current or past clinical evidence of cirrhosis such as ascites or esophageal varices, or prior biopsy showing cirrhosis or advanced bridging fibrosis, e.g., a Metavir score \\> 2 or an Ishak score \\> 3\n4. Use of medications contraindicated for ombitasvir/paritaprevir/ritonavir, dasabuvir, sofosbuvir, or ribavirin (RBV; for those that receive RBV), within 2 weeks or 10 half-lives whichever is longer, prior to study drug administration\n5. Current enrolment in another clinical study, previous enrolment in this study, or previous use of any investigational or commercially available anti-HCV agents","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment","description":"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \\[HCV RNA\\] level less than the lower limit of quantitation \\[\\< LLOQ\\]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With On-treatment Virologic Failure","description":"Virologic failure during treatment was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \\< LLOQ during treatment; confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements \\> 1 log10 IU/mL above nadir) during treatment; or failure to suppress during treatment (defined as all values of HCV RNA ≥ LLOQ during treatment).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Post-treatment Relapse","description":"Percentage of subjects with HCV RNA less than the lower limit of quantification at the end of treatment with confirmed HCV RNA greater than or equal to the lower limit of quantification through 12 weeks post treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":10},"commonTop":["FATIGUE","INSOMNIA","UPPER RESPIRATORY TRACT INFECTION","HEADACHE","CONSTIPATION"]}}}